People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Pharmaceuticals, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Zelos Therapeutics Inc | — | Pharmaceuticals | Series A | $17.8M | $75.0M | 2009 |
| Ripelocker, Inc. | — | Other Technology | Series A | $12.9M | $1.0M | 2023 |
| Alder Boutique LLC | — | Other Technology | Pre-Seed | $130K | $5.5M | 2018 |
David Krause at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Krause on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Joseph Zakrzewski | 1 | 6 |
| Farah Champsi | 1 | 5 |
| Colin Goddard | 1 | 5 |
| Brian MacDonald | 1 | 4 |
| Scott McFarlane | 1 | 3 |
| Donald Hayden | 1 | 3 |
| Bob Kelly | 1 | 3 |
| Jaisim Shah | 1 | 3 |
| Jeff Courtney | 1 | 3 |
| Alex Barkas | 1 | 3 |
| Thomas Mitchell | 1 | 2 |
| Ray S. Aspiri | 1 | 2 |
| Cynthia Lavoie | 1 | 2 |
| Jeffrey Courtney | 1 | 2 |
| Alan Roemer | 1 | 2 |
| Robert S. Masingill | 1 | 1 |
| Brenton Roy | 1 | 1 |
| Scott Masingill | 1 | 1 |
| David Orem | 1 | 1 |
| David Gonzalez | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.